Metabolism

Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis

Retrieved on: 
星期三, 四月 10, 2024
CTA, PKM2, Partnership, Patient, Metabolism, Lilly, Inflammation, Immune system, Atopic dermatitis, Therapy

SYX-5219 has the potential to address a broad range of inflammatory diseases and will advance into the clinic for the treatment of atopic dermatitis, the most common inflammatory skin disease.

Key Points: 
  • SYX-5219 has the potential to address a broad range of inflammatory diseases and will advance into the clinic for the treatment of atopic dermatitis, the most common inflammatory skin disease.
  • SYX-5219 offers first-in-class potential as an oral, targeted, disease-modifying anti-inflammatory therapy, targeting a critical enzyme that regulates cell metabolism called pyruvate kinase M2 (PKM2).
  • Iain Kilty, Chief Scientific Officer of Sitryx, commented: “The nomination of SYX-5219 as our first clinical development candidate for atopic dermatitis is a hugely exciting development for Sitryx and an important milestone as we transition to a clinical-stage company.
  • The team has generated a strong preclinical data package that builds on the scientific community’s growing understanding of PKM2 and its role in the pathogenesis of atopic dermatitis.

Global Weight Loss Drugs Markets Report 2023-2024 & 2029 - The Emergence of GLP-1 and GIP, Unmet Market Needs and Emerging Product Pipeline - ResearchAndMarkets.com

Retrieved on: 
星期五, 四月 26, 2024
Health, Fitness & Nutrition, Other Science, General Health, Science, Pharmaceutical, Biotechnology, Online, Conditional sentence, Market, Semaglutide, Sale, Investment, Social media, Injection, Weight gain, Huadong Medicine, Safety, Risk, Plasma protein binding, CDC, Underweight, Alli, OTC, Overweight, Eli Lilly, GSK plc, Diabetes, Weight loss, Research, Liraglutide, USFDA, Appetite, Success, Roche, Obesity, Culture, Novo Nordisk, Distribution, Patient, Powder, Metabolism, Marketing, GIP, Cancer, COVID-19, Pharmacy, Growth, Prevalence, Pharmaceutical industry

The global weight loss drugs market was valued at US$3.83 billion in 2023, and is expected to be worth US$44.12 billion in 2029.

Key Points: 
  • The global weight loss drugs market was valued at US$3.83 billion in 2023, and is expected to be worth US$44.12 billion in 2029.
  • The global weight loss drugs market is expected to grow at a CAGR of 49.85% over the years 2024-2029.
  • The weight loss drugs market in the Asia Pacific is expected to grow significantly during the forecasted period.
  • Offline distribution channels, comprising brick-and-mortar pharmacies, clinics, and healthcare facilities, dominated the global weight loss drugs market in 2023.

Lindora Launches Inaugural Challenge to Kickstart Weight Loss Journeys

Retrieved on: 
星期一, 四月 22, 2024
General Health, Fitness & Nutrition, Health, Other Health, Science, Wellness, Countdown, Princess, Weight loss, Immunity, Metabolism, Tourism

Lindora , a leading provider of medically guided weight loss and metabolic health solutions, has officially launched its first Countdown to Summer Challenge .

Key Points: 
  • Lindora , a leading provider of medically guided weight loss and metabolic health solutions, has officially launched its first Countdown to Summer Challenge .
  • Through April 30th, Lindora invites clients to start a wellness membership and join a 10-week weight loss program to achieve a personal goal, ahead of summer, and with support from Lindora medical staff and member community.
  • “At Lindora, our medically-guided wellness memberships and 10-week weight loss programs have helped hundreds of thousands of clients set and achieve their weight loss goals,” said Dr. Amy Lee, Chief Medical Advisor for Lindora.
  • “As we continue our mission to lead the metabolic health movement, we’re thrilled to launch the Lindora Countdown to Summer Challenge to encourage individuals to start their weight loss journey at Lindora where our science, our staff and our community offer support throughout the program.

Metsera Launches to Lead the Next Generation of Medicines for Obesity and Metabolic Diseases

Retrieved on: 
星期四, 四月 18, 2024
Health, Fitness & Nutrition, General Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, GV, Digestion, Capital, ARCH Venture Partners, Reproduction, FRS, Weight loss, Research, Imperial College London, Obesity, Patient, DSM-IV codes, Peptide, Metabolism, Head, Drug development, Fine chemical

Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, announced its launch today.

Key Points: 
  • Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, announced its launch today.
  • “Metsera was purpose-built over the last two years to get ahead of the innovation curve in one of the largest and fastest growing markets in the history of biopharma,” said Clive Meanwell, chief executive officer of Metsera.
  • “We have assembled a portfolio of long-acting injectable and oral agents to address multiple next-generation weight loss goals.
  • “Through optimized combinations of injectable and oral peptides, we aim to establish a cycle of continuous and responsive innovation to address a growing worldwide obesity crisis.”

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

Retrieved on: 
星期一, 四月 15, 2024
Biotechnology, Pharmaceutical, Health, Oncology, FDA, Phase, Biomedicine, Food, Hepatocellular carcinoma, Metabolism, KOL, Science, European Medicines Agency, Patient, EMA, Medicine, Inflammation, Multimedia, Manuscript, Liver cancer, CANF, Head, HCC, Medical device

Biomedicines is a highly reputable journal that publishes articles on clinical and basic science topics in medicine.

Key Points: 
  • Biomedicines is a highly reputable journal that publishes articles on clinical and basic science topics in medicine.
  • Dr. Etzion is the Head, Department of Gastroenterology and Liver Diseases, at Soroka University Medical Center, Beer Sheva, Israel.
  • This dual activity enables the drug to have positive effects in both liver cancer and MASH.
  • The drug mechanism of action which is presented in the manuscript and entails inflammatory cytokine inhibition together with the stimulation of positive cytokines, position Namodenoson as a promising safe drug,” stated Dr. Etzion.

FASENRA approved for treatment of children aged 6 to 11 with severe asthma

Retrieved on: 
星期四, 四月 11, 2024
Health, FDA, General Health, Research, Science, Pharmaceutical, Biotechnology, Efficacy, Safety, Gastroenterology, HES, Chronic obstructive pulmonary disease, Sinusitis, Social media, Polyp (medicine), Pharmacokinetics, Rheumatology, Conference call, Asthma, TATE, AstraZeneca, FY, Hypereosinophilic syndrome, Death, ClinicalTrials.gov, Dermatology, Conference, COPD, Webcast, Growth, Disease, Vasculitis, Respiratory Medicine, EGPA, Immunology, Metabolism, Diagnosis, Biomarker, PD, Biopharmaceutical, Ageing, Pharmaceutical industry

TATE was an open-label, Phase III trial evaluating the safety of FASENRA in children aged 6 to 11 years with severe eosinophilic asthma.

Key Points: 
  • TATE was an open-label, Phase III trial evaluating the safety of FASENRA in children aged 6 to 11 years with severe eosinophilic asthma.
  • The Company aims to transform the treatment of asthma and COPD by focusing on earlier biology-led treatment, eliminating preventable asthma attacks, and removing COPD as a top-three leading cause of death.
  • Benralizumab in children with severe eosinophilic asthma: pharmacokinetics and long-term safety (TATE study).
  • Severe uncontrolled asthma in children: practical approach on diagnosis and management.

AMRA Medical’s Innovative Fat Z-Score Biomarkers Show Tirzepatide Treatment is Associated with a Potential Targeted Effect on Visceral Fat and Liver Fat

Retrieved on: 
星期三, 四月 10, 2024
Biotechnology, Other Health, Diabetes, Health, General Health, Pharmaceutical, Health Technology, Other Science, Research, Surgery, Science, Disorder, T2D, Connective tissue, Bariatric surgery, Eli Lilly, Human, Weight, Tirzepatide, Metabolism, Obesity, Type 2 diabetes, Patient, Society, Magnetic resonance imaging, MRI, Multimedia, ASMBS, Medical imaging

For this reason, fat distribution profiling through personalized z-score assessment would represent an attractive and modifiable endpoint for future therapeutic efficacy trials in obesity and related disorders.

Key Points: 
  • For this reason, fat distribution profiling through personalized z-score assessment would represent an attractive and modifiable endpoint for future therapeutic efficacy trials in obesity and related disorders.
  • The personalized fat z-scores were introduced through research published in 2023 linking fat distribution patterns, as described by the z-scores, to specific cardiometabolic disease risk profiles in the general population.
  • The results showed that treatment with tirzepatide was associated with a significant reduction in visceral fat z-score (-0.18 SD) and liver fat z-score (-0.54 SD), while the subcutaneous fat z-score increased from an initially negative value (+0.11 SD) - suggesting a therapeutically-induced shift towards a better-balanced body fat distribution with prominent visceral and liver fat loss.
  • The significant reduction of visceral fat and liver fat z-scores observed with tirzepatide in SURPASS-3 MRI indicates a potential targeted effect beyond that expected by the magnitude of weight reduction.

Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome

Retrieved on: 
星期三, 四月 10, 2024
Health, Diabetes, Neurology, Genetics, Clinical Trials, Pharmaceutical, FDA, DSM-IV codes, Glycated hemoglobin, Cell, Safety, PB, Blood, Apoptosis, Paratriathlon, C-peptide, Endoplasmic reticulum, Doctor of Philosophy, WFS1, Disease, AMX0035, Week, Wolfram syndrome, Science, Snellen, Patient, Diarrhea, Amylyx Pharmaceuticals, Data analysis, PGIC, Samuel, Metabolism, Aes, Visual acuity, Clinical trial, AUC, Medication, Division, Pharmaceutical industry

“I have been studying Wolfram syndrome and caring for people with the disease for more than 20 years.

Key Points: 
  • “I have been studying Wolfram syndrome and caring for people with the disease for more than 20 years.
  • Outcomes for people with Wolfram syndrome consistently worsen over time, so disease stabilization alone is clinically meaningful for both patients and their doctors.
  • Because of the clear link between WFS1 mutations and ER stress, Wolfram syndrome is considered a prototypical ER stress disorder.
  • Amylyx announced that the FDA granted orphan drug designation to AMX0035 for the treatment of Wolfram syndrome in November 2020.

Pinnacle Clinical Research Statement on Founder and Chairman Dr. Stephen Harrison

Retrieved on: 
星期四, 四月 25, 2024
Hepatology, FDA, MASH, University, Army, Gastroenterology, Graduate medical education, LVC, University of Oxford, Death, Health care, Publishing, MD, Research, Dean (education), Brooke Army Medical Center, Metabolism, Growth, CNS, Family, Patient, Pinnacle, SAN, Medical device

SAN ANTONIO, April 25, 2024 /PRNewswire/ -- Pinnacle Clinical Research, LLC ("Pinnacle") is deeply saddened by the death of Founder and Chairman Dr. Stephen Harrison.

Key Points: 
  • SAN ANTONIO, April 25, 2024 /PRNewswire/ -- Pinnacle Clinical Research, LLC ("Pinnacle") is deeply saddened by the death of Founder and Chairman Dr. Stephen Harrison.
  • Pinnacle mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.
  • "We are profoundly saddened by Dr. Harrison's passing," said Rashmee Patil, MD, Hepatologist & Chief Executive Officer of Pinnacle Clinical Research.
  • Dr. Harrison was the Founder and Chairman of Pinnacle Clinical Research, and the Co-Founder and Chairman of Summit Clinical Research in San Antonio, Texas, among others.

Savanna Ingredients GmbH Appoints Palmer Holland as Exclusive Distribution Partner

Retrieved on: 
星期四, 四月 25, 2024
Psicose, Sucrose, Nutrition, Solubility, GMO, Partnership, Food industry, Metabolism, Cellobiose, Convenience food

CLEVELAND, April 24, 2024 /PRNewswire/ -- Savanna Ingredients GmbH and Palmer Holland, Inc. have signed an exclusive distribution partnership for crystalline Allulose and Cellobiose in the USA and Canada markets.

Key Points: 
  • CLEVELAND, April 24, 2024 /PRNewswire/ -- Savanna Ingredients GmbH and Palmer Holland, Inc. have signed an exclusive distribution partnership for crystalline Allulose and Cellobiose in the USA and Canada markets.
  • "Savanna Ingredients GmbH's value proposition and focus on quality and sustainability aligns well with Palmer Holland's mission to source high-quality natural ingredients designed to meet the needs of tomorrow," said Brendan Michel, Palmer Holland Business Manager - Health and Nutrition.
  • Allulose does not dock in the body, the calories are not metabolized but excreted," said Ralph Cartarius, Managing Director of Savanna Ingredients GmbH.
  • Another promising innovation from Savanna Ingredients GmbH is the functional carbohydrate Cellobiose.